Overview
PNC-27 is an experimental 32-residue peptide composed of two parts: a segment of the p53 tumour suppressor protein, residues 12 to 26, which forms part of its binding interface with HDM-2, joined to a membrane-residency sequence derived from the penetratin domain of the Drosophila Antennapedia homeodomain. It was designed and studied primarily by Matthew Pincus, Josef Michl, Wilbur Bowne and colleagues at SUNY Downstate Medical Center in the 2000s.
PNC-27 is not approved by any regulator and remains at the in vitro studies and animal models.">preclinical stage. The published evidence consists mainly of cell culture studies and a limited number of animal experiments, largely from the originating research group. These reported that PNC-27 killed a range of cancer cell lines while sparing non-transformed cells, an effect attributed to its interaction with HDM-2 present on cancer cell membranes. Independent replication is limited, and no controlled clinical trials have been published. PNC-27 is therefore best understood as an interesting hypothesis in membrane-targeted peptide design rather than an established anticancer agent.
Mechanism studied
- PNC-27
- Membrane HDM-2
- Pore formation
- Tumour cell lysis (in vitro)
The proposed mechanism centres on HDM-2, the human homologue of MDM2, which normally binds p53 inside the cell and targets it for degradation. Studies from the originating group reported that HDM-2 is also present in the plasma membranes of many cancer cells but not of normal cells. The p53-derived segment of PNC-27 is thought to bind this membrane HDM-2, while the penetratin segment anchors the peptide in the lipid bilayer. The complex is proposed to form transmembrane pores, causing rapid membrane disruption and necrotic cell death independent of intracellular p53 status. This model is based mainly on in vitro data.
Research highlights
- 01Designed at SUNY Downstate by combining a p53 HDM-2-binding segment with a penetratin membrane-residency sequence.
- 02In vitro studies reported selective lysis of multiple cancer cell lines with sparing of non-transformed cells.
- 03Proposed pore formation via membrane HDM-2 distinguishes it from intracellular p53-MDM2 inhibitors.
- 04The evidence base is preclinical and largely from one research group, with limited independent replication.
- 05Open questions include the prevalence of membrane HDM-2, stability in biological fluids and behaviour in animal models.
Research areas
- HDM-2 membrane binding
- Tumour cell membranolysis
- p53-derived peptide design
- Cancer cell-line studies
Evidence & regulatory status
Overall status: Not approved — preclinical
Key references
- [1]Michl et al., 2006 — Int J Cancer
- [2]PubMed — reviews on PNC-27 and p53
Latest published research
27 papers on PubMed →HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells
Krzesaj PK et al. · Annals of clinical and laboratory science · 2025 May · PMID 40750238
Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells
Pincus MR et al. · Biomedicines · 2024 May 22 · PMID 38927351
Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption
Krzesaj P et al. · Annals of clinical and laboratory science · 2024 Mar · PMID 38802154
Ketone Bodies Induce Unique Inhibition of Tumor Cell Proliferation and Enhance the Efficacy of Anti-Cancer Agents
Miller AI et al. · Biomedicines · 2023 Sep 12 · PMID 37760956
The role of ETFS amino acids on the stability and inhibition of p53-MDM2 complex of anticancer p53-derivatives peptides: Density functional theory and molecular docking studies
Soriano-Correa C et al. · Journal of molecular graphics & modelling · 2023 Jul · PMID 37086514
Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study
Rahmani R et al. · Iranian journal of basic medical sciences · 2022 Oct · PMID 36311203
PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis
Sarafraz-Yazdi E et al. · Biomedicines · 2022 Apr 20 · PMID 35625682
Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells
Thadi A et al. · Anticancer research · 2021 Jan · PMID 33419797
Live feed from PubMed (NCBI) for “PNC-27”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.
FAQ
No. PNC-27 is not approved by the FDA, EMA or any other regulator, and no controlled clinical trials have been published. Its evidence base is preclinical, consisting mainly of cell culture and limited animal studies.
PNC-27 combines residues 12 to 26 of p53, which take part in binding HDM-2, with a penetratin sequence from the Antennapedia homeodomain. The penetratin portion is intended to hold the peptide within cell membranes.
The evidence level is very low. Most findings come from in vitro experiments conducted by the originating laboratory, and independent replication is limited. Its proposed mechanism and selectivity remain hypotheses requiring further investigation.
Last updated October 2026 · Reviewed by the Purity Peptides research team · Information is a summary of published literature and is not a recommendation for any use.
